Australia markets closed

Velan Inc. (VLNSF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
6.690.00 (0.00%)
At close: 02:24PM EST
Full screen
Trade prices are not sourced from all markets
Previous close6.69
Bid0.00 x 0
Ask0.00 x 0
Day's range6.69 - 6.69
52-week range5.50 - 9.09
Avg. volume43
Market cap147.66M
Beta (5Y monthly)1.19
PE ratio (TTM)30.15
EPS (TTM)0.22
Earnings date12 Jan 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend date11 Mar 2020
1y target estN/A
  • GlobeNewswire

    Velan Inc. Reports Its Strong Third Quarter 2021/22 Financial Results, Highlighted by a Significant Increase in Sales and Improved Margins

    MONTREAL, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Velan Inc. (TSX: VLN) (the “Company”), a world-leading manufacturer of industrial valves, announced today its financial results for its third quarter ended November 30, 2021. Highlights: Sales for the quarter amounted to $110.0 million, an increase of 38.4 million or 53.7% compared to the same quarter of the previous fiscal year. This quarter’s sales level represents the highest volume in the last seven quarters.Gross profit for the quarter of $35.9 mi

  • GlobeNewswire

    Velan Inc.: Announcement

    MONTREAL, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Velan Inc. (TSX: VLN) today announced that, on Wednesday, January 12th, 2022, it will release its financial results for the third quarter ended November 30, 2021. The company will hold an analyst call on Thursday, January 13th, 2022, at 11:00 A.M. (Eastern Daylight Time) to discuss the results. The call may be accessed by dialing 1-800-954-0653 and quoting the reservation number 22014449. Live content to support the discussion will be presented to part

  • GlobeNewswire

    Nemaura Medical Completes Initial Shipment of CGM Devices to UK Licensee

    Sales in UK expected to be followed by launches across major EU territories in 2022 Loughborough, England, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces that it has completed its initial shipment of sugarBEAT® continuous glucose monitor (CGM) devices to its UK licens